VivoSeq
Oncology

Unresectable Solid Tumor

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Unresectable Solid Tumor is an early-stage landscape with 0 programs across 4 companies. The most active players are FutureGen Biopharmaceutical (Beijing) Co., Ltd, Eisai, Fore Biotherapeutics.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

FutureGen Biopharmaceutical (Beijing) Co., Ltd

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalF

Fore Biotherapeutics

0 programs

PreclinicalA

Andes Biotechnologies

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

33

clinical trials

Completed25 · 76%
Active, not recruiting4 · 12%
Terminated3 · 9%
Unknown status1 · 3%

Clinical Trials

Trial Activity

33 trials

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04957615·16 enrolled
Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid Tumors
Active, not recruiting·TThe Second Hospital of Shandong University·Phase 1·NCT06572956·10 enrolled
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04266912·23 enrolled
A Phase I Trial of Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT05831579·24 enrolled
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00089362·30 enrolled
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·MMayo Clinic·Phase 1·NCT00005068
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Completed·National Cancer Institute (NCI)·Phase 1·NCT00087217·35 enrolled
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Completed·PPharmaMar·Phase 1·NCT01970540·122 enrolled
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00078962·40 enrolled
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·UUniversity Health Network, Toronto·Phase 1·NCT00126620·17 enrolled
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
Completed·PPharmaMar·Phase 1·NCT01970553·47 enrolled
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00074321·84 enrolled
Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00368914·30 enrolled
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00042861
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
Completed·RRoswell Park Cancer Institute·Phase 1·NCT00238225·15 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)